ProCE Banner Activity

Updated Results of a Phase I/IIa Trial of CLN-081, a Selective EGFR TKI, in Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations

Slideset Download
Conference Coverage
Manageable safety and promising antitumor activity observed with CLN-081 in patients with previously treated advanced NSCLC harboring EGFR exon 20 insertion mutations.

Released: June 10, 2022

Expiration: June 09, 2023

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BMS

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen and Genmab